Conexeu Sciences Inc. quarterly report, Q3 FY2026

Conexeu Sciences Inc. (CNXU) - 10-Q Summary

Business Context and Reporting Period

Company: Conexeu Sciences Inc.
Reporting Period: Quarter and nine months ended July 31, 2026.
Business Overview: An early-stage regenerative medicine company developing biomaterial-based technologies for tissue restoration in wound care and aesthetics. The Company has no commercial sales to date.
Key Milestone: Commenced trading on the Nasdaq Capital Market under symbol "CNXU" via a direct listing on May 21, 2026.

Key Financial Metrics

Metric Three Months Ended July 31, 2026 Nine Months Ended July 31, 2026 Balance Sheet (July 31, 2026)
Revenue $0 $0 N/A
Net Loss $(7,725,651) $(11,748,757) N/A
Loss Per Share (Basic/Diluted) $(0.29) $(0.52) N/A
Cash & Cash Equivalents N/A N/A $1,971,408
Restricted Cash N/A N/A $238,208
Total Assets N/A N/A $7,156,074
Total Liabilities N/A N/A $1,305,684
Accumulated Deficit N/A N/A $(16,270,277)
Net Cash Used in Operating Activities N/A $(10,099,279) N/A
Net Cash Provided by Financing Activities N/A $7,548,009 N/A

Material Changes vs. Prior Period

  • Operating Expenses: Total operating expenses increased significantly to $7.69 million for the quarter (from $1.30 million in the prior year quarter) and $11.79 million for the nine-month period (from $2.09 million).
    • Consulting: Increased by $3.32 million (quarter) and $4.78 million (nine months), driven largely by non-cash stock-based compensation issued to marketing and advisory vendors valued at Nasdaq trading prices.
    • Business Development: Increased by $1.18 million (quarter) and $1.26 million (nine months), reflecting expanded marketing, investor relations, and travel costs associated with the Nasdaq listing.
    • Management & Personnel: Increased by $1.06 million (quarter) due to executive team expansion and vesting of milestone warrants.
    • Regulatory Fees: Increased by $206,371 (quarter) related to 510(k) submission preparations.
  • Prepaid Expenses: Increased from $549,930 to $4,544,274, primarily due to $3.7 million in prepaid marketing and business development contracts.
  • Financing: Net cash provided by financing activities rose to $7.55 million (nine months), driven by the collection of a $2.0 million private placement receivable and proceeds from a Warrant Exercise Incentive Program.

Guidance, Outlook, Risks, and Unusual Items

  • Going Concern: The Company has incurred recurring losses and an accumulated deficit of $16.3 million. Management states that existing cash resources are not sufficient to fund operations for the next twelve months, raising substantial doubt about the ability to continue as a going concern. Additional financing is required.
  • Cash Burn: Average monthly cash burn was approximately $0.87 million for the quarter ended July 31, 2026, excluding one-time prepaid expenses. Including prepayments, the burn rate was higher ($2.3 million/month).
  • Outlook: The Company anticipates submitting a 510(k) application to the FDA in the first quarter of calendar 2027. No revenue is expected in the near term.
  • Unusual Items:
    • Write-off of $73,169 in deferred offering costs due to the shift from an IPO to a direct listing.
    • Significant non-cash stock-based compensation ($4.6 million for the nine months) related to shares and options issued for services.
  • Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of July 31, 2026, due to a material weakness in the accounting for and disclosure of certain prepaid expenses. Remediation is underway.
  • Subsequent Events: On September 4, 2026, the Company raised $1.75 million through warrant exercises.

Investor Verification Checklist

  • Liquidity Runway: Verify the timeline for securing additional debt or equity financing given the stated inability to fund operations for 12 months.
  • Prepaid Expense Recognition: Monitor the amortization schedule of the $3.7 million in prepaid marketing expenses to understand future cash burn impacts.
  • Internal Control Remediation: Track progress on fixing the material weakness regarding prepaid expense accounting to ensure future financial reporting reliability.
  • Regulatory Milestones: Confirm the timeline for the planned 510(k) FDA submission (anticipated Q1 2027) and associated costs.
  • Dilution Risk: Review the impact of outstanding warrants (approx. 7.98 million) and options (735,000) on future share count and ownership dilution.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.